| Metabolite of hydroxyzine. Usual dose: 5-10 mg orally once daily.
Children >/= 6 years and Adults:
Elderly Initial: 5 mg once daily; may increase to 10 mg/day. Note: Manufacturer recommends 5 mg/day in patients >/= 77 years of age.
Dosage adjustment in renal/hepatic impairment:
Allergic rhinitis, seasonal/perennial: 5 mg po qd.
Chronic idiopathic urticaria: 5 mg po qd. In patients with liver or renal impairment, a starting dose of one 5 mg tablet every other day is recommended based on pharmacokinetic data.
Mechanism of Action
Results of a radiolabeled tissue distribution study in rats and a radioligand H1-receptor binding study in guinea pigs showed that desloratadine did not readily cross the blood brain barrier.
Dosing: Oral: Children:
Children >/= 12 years and Adults: 5 mg once daily
Tablet (Clarinex®): 5 mg
Tablet, orally-disintegrating (Clarinex® RediTabs®): 5 mg [contains phenylalanine 1.75 mg/tablet]
| Adult (usual) Chronic idiopathic urticaria: 60 mg orally twice daily.
Seasonal allergic rhinitis: 60 mg orally twice daily or 180 mg once daily. A dose of 60 mg once daily is recommended as the starting dose in patients with decreased renal function
Mechanism of Action
Dosage – Oral:
Children >/= 12 years and Adults:
Oral: Seasonal allergic rhinitis, chronic idiopathic urticaria:
Children 2-5 years: 5 mg once daily
Children >/= 6 years and Adults: 10 mg once daily
Elderly: Peak plasma levels are increased; elimination half-life is slightly increased; specific dosing adjustments are not available
Dosage adjustment in renal impairment: Clcr </= 30 mL/minute:
| Dosing (Adult): 1 tablet orally every 4 to 6 hours as needed.
Maximum of 4 tablets/day.
| (pseudoephedrine 120mg + fexofenadine 60mg).
Dosing:: one tablet twice daily for adults and children 12 years of age and older (should be taken on an empty stomach).
A dose of one tablet once daily is recommended as the starting dose in patients with decreased renal function.
| Claritin-D 24 hour (10mg loratadine + 240mg psuedophedrine)
Dosing (Adult): one tablet po qd.
Claritin-D 24 Hour Extended Release Tablets should generally be avoided in patients with hepatic insufficiency. Patients with renal insufficiency (GFR <30 L/min) should be given a lower initial dose (one tablet every other day) because they have reduced clearance of loratadine and pseudoephedrine. Patients who have a history of difficulty in swallowing tablets or who have known upper gastrointestinal narrowing or abnormal esophageal peristalsis should not use this product.
| Drug UPDATES: Karbinal™ ER (carbinoxamine maleate) extended-release oral suspension
[Drug information / PDF]
Dosing: Click (+) next to Dosage and Administration section (drug info link)
Initial U.S. Approval: 2013
Mechanism of Action: Carbinoxamine is an H1 receptor antagonist (antihistamine) that exhibits anticholinergic (drying) and sedative properties.
INDICATIONS AND USAGE:
Seasonal and perennial allergic rhinitis (1)
DOSAGE AND ADMINISTRATION
Adults and Adolescents 12 years of age and older:
Children 2 to 11 years of age (approximately 0.2 to 0.4 mg/kg/day):
HOW SUPPLIED: Extended-release oral suspension containing 4 mg carbinoxamine maleate per 5 mL
| Adult (usual): 4 mg po every 4 to 6 hrs; maximum dose: 24 mg/day. Sustained-release: 8 or 12 mg po every 8 to 12 hours. Maximum dose: 24 mg/day.
Extended Release Cap: 6 mg, 8 mg, 12 mg
Liquid/syrup: 2 mg/5 ml
Tablet: 2 mg, 4 mg. Chewable: 2 mg
EExtended Release tab: 8 mg, 12 mg, 16 mg
| Tavist 12 Hour Allergy Tablets: Clemastine fumarate, USP 1.34 mg (equivalent to 1 mg clemastine).
Adults and children 12 years of age and older: take 1 tablet every 12 hours, not more than 2 tablets in 24 hours unless directed by a doctor.
| Mechanism of Action
Cyproheptadine is a serotonin and histamine antagonist with anticholinergic and sedative effects. Antiserotonin and antihistamine drugs appear to compete with serotonin and histamine, respectively, for receptor sites.
Dosage – Oral: Children:
2-6 years: 2 mg every 8-12 hours (not to exceed 12 mg/day)
Migraine headaches: 4 mg 2-3 times/day
Children >/= 12 years and Adults: Spasticity associated with spinal cord damage: 4 mg at bedtime; increase by a 4 mg dose every 3-4 days; average daily dose: 16 mg in divided doses; not to exceed 36 mg/day
Children >13 years and Adults: Appetite stimulation (anorexia nervosa): 2 mg 4 times/day; may be increased gradually over a 3-week period to 8 mg 4 times/day
| Dosage – Oral: Children:
2-5 years: 12.5-25 mg every 6-8 hours, maximum: 75 mg/day
6-12 years: 25-50 mg every 6-8 hours, maximum: 150 mg/day
Adults: 50-100 mg every 4-6 hours, not to exceed 400 mg/day
| Mechanism of Action
Diphenhydramine hydrochloride is an antihistamine with anticholinergic (drying) and sedative side effects. Antihistamines appear to compete with histamine for cell receptor sites on effector cells.
Diphenhydramine hydrochloride in the injectable form has a rapid onset of action. Diphenhydramine hydrochloride is widely distributed throughout the body, including the CNS. A portion of the drug is excreted unchanged in the urine, while the rest is metabolized via the liver. Detailed information on the pharmacokinetics of diphenhydramine hydrochloride injection is not available.
Dosing- Children: Oral, I.M., I.V.:
Minor allergic rhinitis or motion sickness:
Night-time sleep aid: 30 minutes before bedtime:
I.M., I.V.: Treatment of dystonic reactions: 0.5-1 mg/kg/dose
I.M., I.V.: 10-50 mg in a single dose every 2-4 hours, not to exceed 400 mg/day
Topical: For external application, not longer than 7 days
| Adult (usual):
Antiemetic: I.M.: 25-100 mg/dose every 4-6 hours as needed.
Anxiety: Oral: 25-100 mg 4 times/day; maximum: 600 mg/day.
Preoperative sedation: Oral: 50-100 mg. I.M.: 25-100 mg.
Management of pruritus: Oral: 25 mg 3-4 times/day
Intravenous, intra-arterial, and subcutaneous administration are not recommended since thrombosis and digital gangrene can occur
| Adult (usual)
Allergy: 25 mg orally at bedtime or 12.5 mg orally before meals and at bedtime. Allergy: 25 mg IV or IM, may repeat within 2 hrs if needed.
Anesthesia adjunct: 25-50 mg IM or IV prior to surgery.
Motion sickness: 25 mg orally twice daily.
Nausea and vomiting: 12.5-25 mg orally ,rectally, IV or IM every 4 to 6 hrs.
Sedation: 25-50 mg orally or 50 mg rectally.
Administer I.M. into deep muscle (preferred route of administration). Due to the possibility of orthostatic hypotension, I.V. administration is not the preferred route. Solution for injection may be diluted in 25-100 mL NS or D5W (maximum concentration of 25 mg/mL) and infused over 15-30 minutes at a rate </= 25 mg/minute.
[Supplied: 25, 50 mg/ml Injection. 12.5, 25, 50mg suppository. 10 mg/5 ml Syrup. 10, 25 , 50mg Tablet]
National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user’s use of or reliance upon this material.PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read the disclaimer